215 related articles for article (PubMed ID: 21278395)
21. Bilateral toxoplasma retinochoroiditis in a patient with chronic myeloid leukemia treated with imatinib mesylate.
Basu S; Das T; Biswas G
Ocul Immunol Inflamm; 2010 Jan; 18(1):64-5. PubMed ID: 20128654
[TBL] [Abstract][Full Text] [Related]
22. Transient trisomy 8 abnormality in Philadelphia-negative cells during imatinib mesylate treatment of chronic myelogenous leukemia.
Kim M; Lee S; Jung CK; Lim J; Cho SG; Kim DW; Kim Y; Han K; Min WS; Kim CC
Int J Lab Hematol; 2008 Dec; 30(6):508-12. PubMed ID: 18983302
[TBL] [Abstract][Full Text] [Related]
23. Imatinib-associated hyperpigmentation, a side effect that should be recognized.
Mcpherson T; Sherman V; Turner R
J Eur Acad Dermatol Venereol; 2009 Jan; 23(1):82-3. PubMed ID: 18384557
[No Abstract] [Full Text] [Related]
24. Chronic myelogenous leukemia therapy beyond imatinib.
Deininger M
Clin Adv Hematol Oncol; 2010 Mar; 8(3):178-80. PubMed ID: 20400933
[No Abstract] [Full Text] [Related]
25. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
26. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
Druker BJ; Guilhot F; O'Brien SG; Gathmann I; Kantarjian H; Gattermann N; Deininger MW; Silver RT; Goldman JM; Stone RM; Cervantes F; Hochhaus A; Powell BL; Gabrilove JL; Rousselot P; Reiffers J; Cornelissen JJ; Hughes T; Agis H; Fischer T; Verhoef G; Shepherd J; Saglio G; Gratwohl A; Nielsen JL; Radich JP; Simonsson B; Taylor K; Baccarani M; So C; Letvak L; Larson RA;
N Engl J Med; 2006 Dec; 355(23):2408-17. PubMed ID: 17151364
[TBL] [Abstract][Full Text] [Related]
27. Oral mucosal hyperpigmentation and horizontal melanonychia caused by imatinib.
Steele JC; Triantafyllou A; Rajlawat BP; Field EA
Clin Exp Dermatol; 2012 Jun; 37(4):432-3. PubMed ID: 22420895
[No Abstract] [Full Text] [Related]
28. [The role of imatinib in the treatment of acute lymphoid leukemias].
Poros A; Lovas N
Orv Hetil; 2005 May; 146(18 Suppl 1):905-10. PubMed ID: 15921303
[TBL] [Abstract][Full Text] [Related]
29. [Chronic myeloid leukemia and imatinib mesylate therapy].
Chrobák L
Vnitr Lek; 2004 Jan; 50(1):10-2. PubMed ID: 15015223
[No Abstract] [Full Text] [Related]
30. [Perspectives in the use of imatinib in the treatment of childhood cancers].
Balwierz W; Pawińska K; Skoczeń S; Klekawka T; Strojny W; Niezgoda A
Przegl Lek; 2004; 61 Suppl 2():95-9. PubMed ID: 15686056
[TBL] [Abstract][Full Text] [Related]
31. Tumour lysis syndrome with acute renal failure during imatinib therapy.
Ali R; Ozkalemkas F; Ozkan A; Ozcelik T; Ozkocaman V; Akdag I; Ozan U; Tunali A
Leuk Res; 2007 Apr; 31(4):573-4. PubMed ID: 16782190
[No Abstract] [Full Text] [Related]
32. [Imatinib--a new perspective in the treatment of tumors].
Klener P; Klamová H
Cas Lek Cesk; 2004; 143(9):579-80, 582-3. PubMed ID: 15532894
[TBL] [Abstract][Full Text] [Related]
33. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
Walz C; Sattler M
Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
[TBL] [Abstract][Full Text] [Related]
34. Peripheral neuropathy on imatinib treatment for chronic myeloid leukaemia: suspected adverse drug interaction with amlodipine.
Ross DM
Intern Med J; 2009 Oct; 39(10):708. PubMed ID: 19849764
[No Abstract] [Full Text] [Related]
35. Imatinib: a designer drug, another cutaneous complication.
Dickens E; Lewis F; Bienz N
Clin Exp Dermatol; 2009 Jul; 34(5):603-4. PubMed ID: 19486036
[TBL] [Abstract][Full Text] [Related]
36. [Psoriasis vulgaris exacerbated by imatinib therapy in chronic myelogenous leukemia].
Shimizu K; Kuroda H; Kida M; Watanabe H; Shirao S; Akiyama T; Fujimi A; Tanaka I; Sato T; Matsunaga T; Niitsu Y
Rinsho Ketsueki; 2005 Oct; 46(10):1152-5. PubMed ID: 16440780
[TBL] [Abstract][Full Text] [Related]
37. Imatinib and chronic-phase leukemias.
Boros LG; Lee WN; Cascante M
N Engl J Med; 2002 Jul; 347(1):67-8. PubMed ID: 12097546
[No Abstract] [Full Text] [Related]
38. Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.
Potenza L; Volzone F; Riva G; Soverini S; Martinelli S; Iacobucci I; Gnani A; Barozzi P; Forghieri F; Morselli M; Zanetti E; Maccaferri M; Baccarani M; Martinelli G; Torelli G; Luppi M
Br J Haematol; 2009 Jul; 146(2):227-30. PubMed ID: 19545285
[No Abstract] [Full Text] [Related]
39. Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia.
Al-Kali A; Farooq S; Tfayli A
J Clin Pharm Ther; 2009 Oct; 34(5):607-10. PubMed ID: 19744017
[TBL] [Abstract][Full Text] [Related]
40. [Selective tyrosine kinase inhibitor imatinib (STI571) in haematological and oncological disease].
Hochhaus A
Dtsch Med Wochenschr; 2002 Mar; 127(9):451-6. PubMed ID: 11870560
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
